Product Code Database
A neurotransmitter is a signaling molecule secreted by a neuron to affect another cell across a Chemical synapse. The cell receiving the signal, or target cell, may be another neuron, but could also be a gland or muscle cell. (2025). 9780080430768, Elsevier. ISBN 9780080430768
Neurotransmitters are released from synaptic vesicles into the synaptic cleft where they are able to interact with neurotransmitter receptors on the target cell. Some neurotransmitters are also stored in large dense core vesicles. The neurotransmitter's effect on the target cell is determined by the receptor it binds to. Many neurotransmitters are synthesized from simple and plentiful precursors such as , which are readily available and often require a small number of biosynthetic steps for conversion.
Neurotransmitters are essential to the function of complex neural systems. The exact number of unique neurotransmitters in humans is unknown, but more than 100 have been identified. (2019). 9780128012383, Elsevier. ISBN 9780128012383 Common neurotransmitters include glutamate, GABA, acetylcholine, glycine, dopamine and norepinephrine.
| Amino acids | glycine, glutamate |
| Monoamines | serotonin, epinephrine, dopamine |
| Peptides | substance P, |
| Purines | ATP, GTP |
| Other | nitric oxide, carbon monoxide |
For example, acetylcholine is eliminated by having its acetyl group cleaved by the enzyme acetylcholinesterase; the remaining choline is then taken in and recycled by the pre-synaptic neuron to synthesize more acetylcholine. Other neurotransmitters are able to Diffusion away from their targeted synaptic junctions and are eliminated from the body via the kidneys, or destroyed in the liver. Each neurotransmitter has very specific degradation pathways at regulatory points, which may be targeted by the body's regulatory system or medication. Cocaine blocks a dopamine transporter responsible for the reuptake of dopamine. Without the transporter, dopamine diffuses much more slowly from the synaptic cleft and continues to activate the dopamine receptors on the target cell.
However, given advances in pharmacology, genetics, and chemical neuroanatomy, the term "neurotransmitter" can be applied to chemicals that:
The anatomical localization of neurotransmitters is typically determined using immunocytochemical techniques, which identify the location of either the transmitter substances themselves or of the enzymes that are involved in their synthesis. Immunocytochemical techniques have also revealed that many transmitters, particularly the , are co-localized, that is, a neuron may release more than one transmitter from its synaptic terminal. (2025). 9780878939275, Sinauer Associates. ISBN 9780878939275 Various techniques and experiments such as staining, stimulating, and collecting can be used to identify neurotransmitters throughout the central nervous system. (2025). 9781429242288, Worth Publishers. ISBN 9781429242288
Type I (excitatory) synapses are typically located on the shafts or the spines of dendrites, whereas type II (inhibitory) synapses are typically located on a cell body. In addition, Type I synapses have round synaptic vesicles, whereas the vesicles of type II synapses are flattened. The material on the presynaptic and post-synaptic membranes is denser in a Type I synapse than it is in a Type II, and the Type I synaptic cleft is wider. Finally, the active zone on a Type I synapse is larger than that on a Type II synapse.
The different locations of Type I and Type II synapses divide a neuron into two zones: an excitatory dendritic tree and an inhibitory cell body. From an inhibitory perspective, excitation comes in over the dendrites and spreads to the axon hillock to trigger an action potential. If the message is to be stopped, it is best stopped by applying inhibition on the cell body, close to the axon hillock where the action potential originates. Another way to conceptualize excitatory–inhibitory interaction is to picture excitation overcoming inhibition. If the cell body is normally in an inhibited state, the only way to generate an action potential at the axon hillock is to reduce the cell body's inhibition. In this "open the gates" strategy, the excitatory message is like a racehorse ready to run down the track, but first, the inhibitory starting gate must be removed. (2025). 9781429242288, Worth Publishers. ISBN 9781429242288
Some of the major neurotransmitters are:
In addition, over 100 neuroactive have been found, and new ones are discovered regularly. Many of these are co-released along with a small-molecule transmitter. Nevertheless, in some cases, a peptide is the primary transmitter at a synapse. Beta-Endorphin is a relatively well-known example of a peptide neurotransmitter because it engages in highly specific interactions with opioid receptors in the central nervous system.
Single ions (such as synaptically released zinc) are also considered neurotransmitters by some, as well as some gaseous molecules such as nitric oxide (NO), carbon monoxide (CO), and hydrogen sulfide (H2S). The gases are produced in the neural cytoplasm and are immediately diffused through the cell membrane into the extracellular fluid and into nearby cells to stimulate production of second messengers. Soluble gas neurotransmitters are difficult to study, as they act rapidly and are immediately broken down, existing for only a few seconds.
The most prevalent transmitter is glutamate, which is excitatory at well over 90% of the synapses in the human brain. The next most prevalent is gamma-Aminobutyric Acid, or GABA, which is inhibitory at more than 90% of the synapses that do not use glutamate. Although other transmitters are used in fewer synapses, they may be very important functionally: the great majority of psychoactive drugs exert their effects by altering the actions of some neurotransmitter systems, often acting through transmitters other than glutamate or GABA. Addictive drugs such as cocaine and amphetamines exert their effects primarily on the dopamine system. The addictive opiate drugs exert their effects primarily as functional analogs of opioid peptides, which, in turn, regulate dopamine levels.
Drugs can influence behavior by altering neurotransmitter activity. For instance, drugs can decrease the rate of synthesis of neurotransmitters by affecting the synthetic enzyme(s) for that neurotransmitter. When neurotransmitter syntheses are blocked, the amount of neurotransmitters available for release becomes substantially lower, resulting in a decrease in neurotransmitter activity. Some drugs block or stimulate the release of specific neurotransmitters. Alternatively, drugs can prevent neurotransmitter storage in synaptic vesicles by causing the synaptic vesicle membranes to leak. Drugs that prevent a neurotransmitter from binding to its receptor are called receptor antagonists. For example, drugs used to treat patients with schizophrenia such as haloperidol, chlorpromazine, and clozapine are antagonists at receptors in the brain for dopamine. Other drugs act by binding to a receptor and mimicking the normal neurotransmitter. Such drugs are called receptor . An example of a receptor agonist is morphine, an opiate that mimics effects of the endogenous neurotransmitter β-endorphin to relieve pain. Other drugs interfere with the deactivation of a neurotransmitter after it has been released, thereby prolonging the action of a neurotransmitter. This can be accomplished by blocking re-uptake or inhibiting degradative enzymes. Lastly, drugs can also prevent an action potential from occurring, blocking neuronal activity throughout the central and peripheral nervous system. Drugs such as tetrodotoxin that block neural activity are typically lethal.
Drugs targeting the neurotransmitter of major systems affect the whole system, which can explain the complexity of action of some drugs. Cocaine, for example, blocks the re-uptake of dopamine back into the presynaptic neuron, leaving the neurotransmitter molecules in the synapse for an extended period of time. Since the dopamine remains in the synapse longer, the neurotransmitter continues to bind to the receptors on the postsynaptic neuron, eliciting a pleasurable emotional response. Physical addiction to cocaine may result from prolonged exposure to excess dopamine in the synapses, which leads to the downregulation of some post-synaptic receptors. After the effects of the drug wear off, an individual can become depressed due to decreased probability of the neurotransmitter binding to a receptor. Fluoxetine is a selective serotonin re-uptake inhibitor (SSRI), which blocks re-uptake of serotonin by the presynaptic cell which increases the amount of serotonin present at the synapse and furthermore allows it to remain there longer, providing potential for the effect of naturally released serotonin. AMPT prevents the conversion of tyrosine to L-DOPA, the precursor to dopamine; reserpine prevents dopamine storage within Synaptic vesicle; and deprenyl inhibits monoamine oxidase (MAO)-B and thus increases dopamine levels.
Used to treat myasthenia gravis
Reinforcing effects
Blocks reuptake
Can be used as a topical anesthetic (eye drops)
Used as an appetite suppressant
Cognitive effects
Impairs learning
Impairs synaptic plasticity and certain forms of learning
Reduces the likelihood of seizures
act similar to a neurotransmitter by binding directly to its associated receptor site(s), which may be located on the presynaptic neuron or postsynaptic neuron, or both. Typically, neurotransmitter receptors are located on the postsynaptic neuron, while neurotransmitter are located on the presynaptic neuron, as is the case for monoamine neurotransmitters; in some cases, a neurotransmitter utilizes retrograde neurotransmission, a type of feedback signaling in neurons where the neurotransmitter is released postsynaptically and binds to target receptors located on the presynaptic neuron. Nicotine, a compound found in tobacco, is a direct agonist of most nicotinic acetylcholine receptors, mainly located in cholinergic neurons. , such as morphine, heroin, hydrocodone, oxycodone, codeine, and methadone, are μ-opioid receptor agonists; this action mediates their and analgesia properties.
increase the binding of neurotransmitters at their target receptors by stimulating the release or preventing the reuptake of neurotransmitters. Some indirect agonists releasing agent and prevent neurotransmitter reuptake. Amphetamine, for example, is an indirect agonist of postsynaptic dopamine, norepinephrine, and serotonin receptors in each their respective neurons; it produces both neurotransmitter release into the presynaptic neuron and subsequently the synaptic cleft and prevents their reuptake from the synaptic cleft by activating TAAR1, a presynaptic G protein-coupled receptor, and binding to a site on VMAT2, a type of monoamine transporter located on synaptic vesicles within monoamine neurons.
There are two main types of antagonist: direct-acting Antagonist and indirect-acting Antagonists:
A competitive antagonist competes with an agonist for binding to the receptor. As the concentration of antagonist increases, the binding of the agonist is progressively inhibited, resulting in a decrease in the physiological response. High concentration of an antagonist can completely inhibit the response. This inhibition can be reversed, however, by an increase of the concentration of the agonist, since the agonist and antagonist compete for binding to the receptor. Competitive antagonists, therefore, can be characterized as shifting the dose–response relationship for the agonist to the right. In the presence of a competitive antagonist, it takes an increased concentration of the agonist to produce the same response observed in the absence of the antagonist.
An irreversible antagonist binds so strongly to the receptor as to render the receptor unavailable for binding to the agonist. Irreversible antagonists may even form covalent chemical bonds with the receptor. In either case, if the concentration of the irreversible antagonist is high enough, the number of unbound receptors remaining for agonist binding may be so low that even high concentrations of the agonist do not produce the maximum biological response.
Apart from recreational use, medications that directly and indirectly interact with one or more transmitter or its receptor are commonly prescribed for psychiatric and psychological issues. Notably, drugs interacting with serotonin and norepinephrine are prescribed to patients with problems such as depression and anxiety—though the notion that there is much solid medical evidence to support such interventions has been widely criticized.Leo, J., & Lacasse, J. (10 October 2007). The Media and the Chemical Imbalance Theory of Depression. Retrieved 1 December 2014, from http://psychrights.org/articles/TheMediaandChemicalImbalanceTheoryofDepression.pdf Studies shown that dopamine imbalance has an influence on multiple sclerosis and other neurological disorders.
List of neurotransmitters, peptides, and gaseous signaling molecules
{ class="sortable wikitable" style="width:100%"
+ Neurotransmitters
! scope="col" style="width: 15%;" Category
! scope="col" style="width: 24%;" Name
! scope="col" style="width: 6%;" class="unsortable" Abbreviation
! scope="col" style="width: 31%;" Metabotropic
! scope="col" style="width: 24%;" Ionotropic
|: (Arginine) || Arginine || Arg, R ||α2-Adrenergic receptors, imidazoline receptors |
| Small: Amino acids || Aspartate || Asp, D || – |
| Small: Amino acids || Glutamate || Glu, E ||Metabotropic glutamate receptors | , ,
| Small: Amino acids || Gamma-aminobutyric acid || GABA || GABAB receptor | GABAA receptor, GABAA-ρ receptors
| Small: Amino acids || Glycine || Gly, G || – | ,
| Small: Amino acids || D-serine || Ser, S || – |
| Small: Acetylcholine || Acetylcholine || ACh ||Muscarinic acetylcholine receptors | Nicotinic acetylcholine receptors
| Small: Monoamine (Phenylalanine/Tyrosine) || Dopamine || DA || Dopamine receptors, trace amine-associated receptor 1 | –
| Small: Monoamine (Phenylalanine/Tyrosine) || Norepinephrine (noradrenaline) || NE, NAd || Adrenergic receptors | –
| Small: Monoamine (Phenylalanine/Tyrosine) || Epinephrine (adrenaline) || Epi, Ad || Adrenergic receptors | –
| Small: Monoamine (Tryptophan) || Serotonin (5-hydroxytryptamine) || 5-HT || Serotonin receptors (all except 5-HT3) | 5-HT3
| Small: Monoamine (Histidine) || Histamine || H || Histamine receptors | –
| Small: Trace amine (Phenylalanine) || Phenethylamine || PEA || Trace amine-associated receptors TAAR1, TAAR2 | –
| Small: Trace amine (Phenylalanine) || N-methylphenethylamine || NMPEA || TAAR1 | –
| Small: Trace amine (Phenylalanine/Tyrosine) || Tyramine || TYR || TAAR1, TAAR2 | –
| Small: Trace amine (Phenylalanine/Tyrosine) || octopamine || Oct || TAAR1 | –
| Small: Trace amine (Phenylalanine/Tyrosine) || Synephrine || Syn || TAAR1 | –
| Small: Trace amine (Tryptophan) || Tryptamine || || TAAR1, various serotonin receptors | –
| Small: Trace amine (Tryptophan) || N-methyltryptamine || NMT || TAAR1, various serotonin receptors | –
| Lipid || Anandamide || AEA || Cannabinoid receptors | –
| Lipid || 2-Arachidonoylglycerol || 2-AG || Cannabinoid receptors | –
| Lipid || 2-Arachidonyl glyceryl ether || 2-AGE || Cannabinoid receptors | –
| Lipid || N-Arachidonoyl dopamine || NADA || Cannabinoid receptors | TRPV1
| Lipid || Virodhamine || || Cannabinoid receptors | –
| Small: Purine || Adenosine || Ado || Adenosine receptors | –
| Small: Purine || Adenosine triphosphate || ATP || P2Y receptors | P2X receptors
| Small: Purine || Nicotinamide adenine dinucleotide || β-NAD || P2Y receptors | P2X receptors
+
! scope="col" style="width: 15%;" Category
! scope="col" style="width: 24%;" Name
! scope="col" style="width: 6%;" class="unsortable" Abbreviation
! scope="col" style="width: 31%;" Metabotropic
! scope="col" style="width: 24%;" Ionotropic
| Bombesin-like peptides|| Bombesin || || BBR1-2-3 | –
| Bombesin-like peptide|| Gastrin releasing peptide || GRP || – | –
| Bombesin-like peptide|| Neuromedin B || NMB || Neuromedin B receptor | –
| Bradykinins || Bradykinin || || B1, B2 | –
| Amylin family|| Calcitonin || || Calcitonin receptor | –
| Amylin family|Calcitonin/CGRP family|| Calcitonin gene-related peptide || CGRP || CALCRL | –
| Corticotropin-releasing factors|| Corticotropin-releasing hormone || CRH || CRHR1 | –
| Corticotropin-releasing factors|| Urocortin || || CRHR1 | –
| Galanins || Galanin || || GALR1, GALR2, GALR3 | –
| Galanins || Galanin-like peptide || || GALR1, GALR2, GALR3 | –
| Gastrins || Gastrin || || Cholecystokinin B receptor | –
| Gastrins || Cholecystokinin || CCK || Cholecystokinin receptors | –
| || Chromogranin A || ChgA || – | –
| || Adrenocorticotropic hormone || ACTH || ACTH receptor | –
| Melanocortins || Proopiomelanocortin || POMC || Melanocortin 4 receptor | –
| Melanocortins || Melanocyte-stimulating hormones || MSH || Melanocortin receptors | –
| || Vasopressin || AVP || Vasopressin receptors | –
| Neurohypophyseals || Oxytocin || OT || Oxytocin receptor | –
| Neurohypophyseals || Neurophysin I || || – | –
| Neurohypophyseals || Neurophysin II || || – | –
| Neurohypophyseals || Copeptin || || – | –
| Neuromedins || Neuromedin U || NmU ||NmUR1, NmUR2| –
| Neuropeptide B/W || Neuropeptide B || NPB || NPBW1, NPBW2 | –
| Neuropeptide B/W || Neuropeptide S || NPS || Neuropeptide S receptors | –
| Neuropeptide Y || Neuropeptide Y || NY || Neuropeptide Y receptors | –
| Neuropeptide Y || Pancreatic polypeptide || PP || – | –
| Neuropeptide Y || Peptide YY || PYY || – | –
| || Enkephalins || || δ-Opioid receptor | –
| Opioids || Dynorphins || || κ-Opioid receptor | –
| Opioids || Neoendorphins || || κ-Opioid receptor | –
| Opioids || Endorphins || || μ-Opioid receptors | –
| Opioids || Endomorphins || || μ-Opioid receptors | –
| Opioids || Morphine || || μ-Opioid receptors | –
| Opioids || Nociceptin || N/OFQ || Nociceptin receptors | –
| || Orexin A || OX-A || | –
| Orexins || Orexin B || OX-B || | –
| Parathyroid hormone family || Parathyroid hormone-related protein || PTHrP || – | –
| RFamides || Kisspeptin || KiSS || GPR54 | –
| RFamides || Neuropeptide FF || NPFF || NPFF1, NPFF2 | –
| RFamides || Prolactin-releasing peptide || PrRP|| PrRPR | –
| RFamides || Pyroglutamylated RFamide peptide || QRFP || GPR103 | –
| Secretin family || Secretin || || Secretin receptor | –
| Secretins || Motilin || || Motilin receptor | –
| Secretins || Glucagon || || Glucagon receptor | –
| Secretins || Glucagon-like peptide-1 || GLP-1 || Glucagon-like peptide 1 receptor | –
| Secretins || Glucagon-like peptide-2 || GLP-2 || Glucagon-like peptide 2 receptor | –
| Secretins || Vasoactive intestinal peptide || VIP || Vasoactive intestinal peptide receptors | –
| Secretins || Growth hormone–releasing hormone || GHRH || Growth hormone–releasing hormone receptor | –
| Secretins || Pituitary adenylate cyclase-activating peptide || PACAP || ADCYAP1R1 | –
| Somatostatins || Somatostatin || || Somatostatin receptors | –
| Tachykinins || Neurokinin A || || – | –
| Tachykinins || Neurokinin B || || – | –
| Tachykinins || Substance P || || – | –
| Tachykinins || Neuropeptide K || || – | –
| Other || Agouti-related peptide || AgRP | Melanocortin receptor –
| Other || N-Acetylaspartylglutamate || NAAG || Metabotropic glutamate receptor 3 (mGluR3) | –
| Other || Cocaine- and amphetamine-regulated transcript || CART || Unknown Gi/Go-coupled receptor | –
| Other || Gonadotropin-releasing hormone || GnRH|| GnRHR | –
–
| Other || Melanin-concentrating hormone || MCH|| MCHR 1,2 | –
|-
|}
+
! scope="col" style="width: 15%;" Category
! scope="col" style="width: 24%;" Name
! scope="col" style="width: 6%;" class="unsortable" Abbreviation
! scope="col" style="width: 31%;" Metabotropic
! scope="col" style="width: 24%;" Ionotropic
|Gaseous signaling molecule || Nitric oxide || NO || Soluble guanylyl cyclase | –
|Gaseous signaling molecule|| Carbon monoxide || CO || – | Heme bound to potassium channels
|Gaseous signaling molecule|| Hydrogen sulfide || H2S || – | –
Neurotransmitter systems
Neurons expressing certain types of neurotransmitters sometimes form distinct systems, where activation of the system affects large volumes of the brain, called volume transmission. Major neurotransmitter systems include the noradrenaline (norepinephrine) system, the dopamine system, the serotonin system, and the cholinergic system, among others. have a modulatory effect on neurotransmission in monoamine pathways (i.e., dopamine, norepinephrine, and serotonin pathways) throughout the brain via signaling through trace amine-associated receptor 1. A brief comparison of these systems follows:
+Neurotransmitter systems in the brain
Drug effects
Understanding the effects of drugs on neurotransmitters comprises a significant portion of research initiatives in the field of neuroscience. Most neuroscientists involved in this field of research believe that such efforts may further advance our understanding of the circuits responsible for various neurological diseases and disorders, as well as ways to effectively treat and someday possibly prevent or cure such illnesses.
+ Drug–neurotransmitter interactionsCarlson, N. R., & Birkett, M. A. (2017). Physiology of Behavior (12th ed.). Pearson, pp. 100–115.
!Drug
!Interacts with
!Receptor interaction
!Type
!Effects Botulinum toxin (Botox) Acetylcholine – Antagonist Blocks acetylcholine release in PNS
Prevents muscle contractions Black widow spider venom Acetylcholine – Agonist Promotes acetylcholine release in PNS
Stimulates muscle contractions Neostigmine Acetylcholine – – Interferes with acetylcholinerase activity
Increases effects of ACh at receptors
Nicotine Acetylcholine Nicotinic (skeletal muscle) Agonist Increases ACh activity
Increases attention
d-tubocurarine Acetylcholine Nicotinic (skeletal muscle) Antagonist Decreases activity at receptor site Curare Acetylcholine Nicotinic (skeletal muscle) Antagonist Decreases ACh activity
Prevents muscle contractions Muscarine Acetylcholine Muscarinic (heart and smooth muscle) Agonist Increases ACh activity
Toxic Atropine Acetylcholine Muscarinic (heart and smooth muscle) Antagonist Blocks pupil constriction
Blocks saliva production Scopolamine (hyoscine) Acetylcholine Muscarinic (heart and smooth muscle) Antagonist Treats motion sickness and postoperative nausea and vomiting AMPT Dopamine/norepinephrine – – Inactivates tyrosine hydroxylase and inhibits dopamine production Reserpine Dopamine – – Prevents storage of dopamine and other monoamines in synaptic vesicles
Causes sedation and depression Apomorphine Dopamine D2 receptor (presynaptic autoreceptors/postsynaptic receptors) Antagonist (low dose) / direct agonist (high dose) Low dose: blocks autoreceptors
High dose: stimulates postsynaptic receptors Amphetamine Dopamine/norepinephrine – Indirect agonist Releases dopamine, noradrenaline, and serotonin
Blocks reuptake Methamphetamine Dopamine/norepinephrine – – Releases dopamine and noradrenaline
Methylphenidate Dopamine – – Blocks reuptake
Enhances attention and impulse control in ADHD Cocaine Dopamine – Indirect agonist Blocks reuptake into presynapse
Blocks voltage-dependent sodium channels
Deprenyl Dopamine – Agonist Inhibits MAO-B
Prevents destruction of dopamine Chlorpromazine Dopamine D2 Receptors Antagonist Blocks D2 receptors
Alleviates hallucinations MPTP Dopamine – – Results in Parkinson-like symptoms PCPA Serotonin (5-HT) – Antagonist Disrupts serotonin synthesis by blocking the activity of tryptophan hydroxylase Ondansetron Serotonin (5-HT) 5-HT3 receptors Antagonist Reduces side effects of chemotherapy and radiation
Reduces nausea and vomiting Buspirone Serotonin (5-HT) 5-HT1A receptors Partial agonist Treats symptoms of anxiety and depression Fluoxetine Serotonin (5-HT) supports Serotonin reuptake SSRI Inhibits reuptake of serotonin
Treats depression, some anxiety disorders, and OCD Common examples: Prozac and Sarafem Fenfluramine Serotonin (5-HT) – – Causes release of serotonin
Inhibits reuptake of serotonin
Lysergic acid diethylamide Serotonin (5-HT) Post-synaptic 5-HT2A receptors Direct agonist Produces visual perception distortions
Stimulates 5-HT2A receptors in forebrain Methylenedioxymethamphetamine (MDMA) Serotonin (5-HT)/norepinphrine – – Stimulates release of serotonin and norepinephrine and inhibits the reuptake
Causes excitatory and hallucinogenic effects Strychnine Glycine – Antagonist Causes severe muscle spasms Diphenhydramine Histamine Crosses blood–brain barrier to cause drowsiness Tetrahydrocannabinol (THC) Endocannabinoids Cannabinoid (CB) receptors Agonist Produces analgesia and sedation
Increases appetite
Rimonabant Endocannabinoids Cannabinoid (CB) receptors Antagonist Suppresses appetite
Used in smoking cessation MAFP Endocannabinoids – – Inhibits FAAH
Used in research to increase cannabinoid system activity AM1172 Endocannabinoids – – Blocks cannabinoid reuptake
Used in research to increase cannabinoid system activity Anandamide (endogenous) – Cannabinoid (CB) receptors; 5-HT3 receptors – Reduce nausea and vomiting Caffeine Adenosine Adenosine receptors Antagonist Blocks adenosine receptors
Increases wakefulness PCP Glutamate NMDA receptor Indirect antagonist Blocks PCP binding site
Prevents calcium ions from entering neurons
AP5 Glutamate NMDA receptor Antagonist Blocks glutamate binding site on NMDA receptor
Ketamine Glutamate NMDA receptor Antagonist Used as anesthesia
Induces trance-like state, helps with pain relief and sedation NMDA Glutamate NMDA receptor Agonist Used in research to study NMDA receptor
Ionotropic receptor AMPA Glutamate AMPA receptor Agonist Used in research to study AMPA receptor
Ionotropic receptor Allyglycine GABA – – Inhibits GABA synthesis
Causes seizures Muscimol GABA GABA receptor Agonist Causes sedation Bicuculline GABA GABA receptor Antagonist Causes Seizures GABA GABAA receptor Indirect agonists Anxiolytic, sedation, memory impairment, muscle relaxation GABA GABAA receptor Indirect agonists Sedation, memory impairment, muscle relaxation Alcohol GABA GABA receptor Indirect agonist Sedation, memory impairment, muscle relaxation Picrotoxin GABA GABAA receptor Indirect antagonist High doses cause seizures Tiagabine GABA – Antagonist GABA transporter antagonist
Increase availability of GABA
Moclobemide Norepinephrine – Agonist Blocks MAO-A to treat depression Idazoxan Norepinephrine alpha-2 adrenergic autoreceptors Agonist Blocks alpha-2 autoreceptors
Used to study norepinephrine system Fusaric acid Norepinephrine – – Inhibits activity of dopamine beta-hydroxylase which blocks the production of norepinephrine
Used to study norepinephrine system without affecting dopamine system Opiates (opium, morphine, heroin, and oxycodone) Opioids Opioid receptor Agonists Analgesia, sedation, and reinforcing effects Naloxone Opioids – Antagonist Reverses opiate intoxication or overdose symptoms (i.e. problems with breathing)
Agonists
An agonist is a chemical capable of binding to a receptor, such as a neurotransmitter receptor, and initiating the same reaction typically produced by the binding of the endogenous substance. An agonist of a neurotransmitter will thus initiate the same receptor response as the transmitter. In neurons, an agonist drug may activate neurotransmitter receptors either directly or indirectly. Direct-binding agonists can be further characterized as full agonists, ,
/ref>
Antagonists
An antagonist is a chemical that acts within the body to reduce the physiological activity of another chemical substance (such as an opiate); especially one that opposes the action on the nervous system of a drug or a substance occurring naturally in the body by combining with and blocking its nervous receptor.
Drug antagonists
An antagonist drug is one that attaches (or binds) to a site called a receptor without activating that receptor to produce a biological response. It is therefore said to have no intrinsic activity. An antagonist may also be called a receptor "blocker" because they block the effect of an agonist at the site. The pharmacological effects of an antagonist, therefore, result in preventing the corresponding receptor site's agonists (e.g., drugs, hormones, neurotransmitters) from binding to and activating it. Antagonists may be "competitive" or "irreversible".
Precursors
While intake of neurotransmitter precursors does increase neurotransmitter synthesis, evidence is mixed as to whether neurotransmitter release and postsynaptic receptor firing is increased. Even with increased neurotransmitter release, it is unclear whether this will result in a long-term increase in neurotransmitter signal strength, since the nervous system can adapt to changes such as increased neurotransmitter synthesis and may therefore maintain constant firing. Some neurotransmitters may have a role in depression and there is some evidence to suggest that intake of precursors of these neurotransmitters may be useful in the treatment of mild and moderate depression.
Catecholamine and trace amine precursors
L-DOPA, a precursor of dopamine that crosses the blood–brain barrier, is used in the treatment of Parkinson's disease. For depressed patients where low activity of the neurotransmitter norepinephrine is implicated, there is only little evidence for benefit of neurotransmitter precursor administration. L-phenylalanine and L-tyrosine are both precursors for dopamine, norepinephrine, and epinephrine. These conversions require vitamin B6, vitamin C, and S-adenosylmethionine. A few studies suggest potential antidepressant effects of L-phenylalanine and L-tyrosine, but there is much room for further research in this area.
Serotonin precursors
Administration of L-tryptophan, a precursor for serotonin, is seen to double the production of serotonin in the brain. It is significantly more effective than a placebo in the treatment of mild and moderate depression. This conversion requires vitamin C. 5-hydroxytryptophan (5-HTP), also a precursor for serotonin, is more effective than a placebo.
Diseases and disorders
The following sections describe how imbalances or dysfunction in specific neurotransmitters—dopamine, serotonin, and glutamate—have been tentatively linked to various mental or neurological disorders.
Dopamine
For example, problems in producing dopamine (mainly in the substantia nigra) can result in Parkinson's disease, a disorder that affects a person's ability to move as they want to, resulting in stiffness, tremors or shaking, and other symptoms. Some studies suggest that having too little or too much dopamine or problems using dopamine in the thinking and feeling regions of the brain may play a role in disorders like schizophrenia or attention deficit hyperactivity disorder (ADHD). Dopamine is also involved in addiction and drug use, as most recreational drugs cause an influx of dopamine in the brain (especially opioid and ) that produces a pleasurable feeling, which is why users constantly crave drugs.
Serotonin
Similarly, after some research suggested that drugs that block the recycling, or reuptake, of serotonin seemed to help some people diagnosed with depression, it was theorized that people with depression might have lower-than-normal serotonin levels. Though widely popularized, this theory was not borne out in subsequent research. Therefore, selective serotonin reuptake inhibitors (SSRIs) are used to increase the amounts of serotonin in synapses.
Glutamate
Furthermore, problems with producing or using glutamate have been suggestively and tentatively linked to many mental disorders, including autism, obsessive–compulsive disorder (OCD), schizophrenia, and depression. Having too much glutamate has been linked to neurological diseases such as Parkinson's disease, multiple sclerosis, Alzheimer's disease, stroke, and ALS (amyotrophic lateral sclerosis).
Neurotransmitter imbalance
Generally, there are no scientifically established "norms" for appropriate levels or "balances" of different neurotransmitters. In most cases, it is practically impossible to measure neurotransmitter levels in the brain or body at any given moment. Neurotransmitters regulate each other's release, and weak consistent imbalances in this mutual regulation were linked to temperament in healthy people.Netter, P. (1991) Biochemical variables in the study of temperament. In Strelau, J. & Angleitner, A. (Eds.), Explorations in temperament: International perspectives on theory and measurement 147–161. New York: Plenum Press.Cloninger CR, Svrakic DM, Przybeck TR. A psychobiological model of temperament and character" Arch Gen Psychiatry 1993; 50:975-990. However, significant imbalances or disruptions in neurotransmitter systems are associated with various diseases and mental disorders, including Parkinson's disease, depression, insomnia, Attention Deficit Hyperactivity Disorder (ADHD), anxiety, memory loss, dramatic weight changes, and addictions. Some of these conditions are also related to neurotransmitter switching, a phenomenon where neurons change the type of neurotransmitters they release. Chronic physical or emotional stress can be a contributor to neurotransmitter system changes. Genetics also plays a role in neurotransmitter activities.
See also
Notes
External links
|
|
